Belvedere Trading’s iShares Biotechnology ETF IBB Stock Holding History

Belvedere Trading’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,800	Closed	-$384K	–	794
2024 Q1	$384K	Buy	+2,800	New	+$382K	﹤0.01%	191

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Belvedere Trading's IBB Position: Q4 2025 in Review

Belvedere Trading sold out of iShares Biotechnology ETF (IBB) in Q4 2025, closing a stake of 2,094 shares — an estimated $302K sold.

Belvedere Trading first reported a position in IBB in Q1 2024 and held it in 2 quarters. The position peaked at $302K in Q3 2025. 956 funds tracked by Wall St. Rank hold IBB as of Q4 2025.

Belvedere Trading reported no remaining iShares Biotechnology ETF position as of Q4 2025 after selling out during the quarter.
Belvedere Trading sold 2,094 iShares Biotechnology ETF shares in Q4 2025, an estimated $302K.
Belvedere Trading first reported a position in iShares Biotechnology ETF in Q1 2024 and held it in 2 quarters.
Belvedere Trading's iShares Biotechnology ETF position peaked at $302K in Q3 2025.
956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2025.

Based on Belvedere Trading's 13F filing for Q4 2025, filed 10 Feb 2026.